Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Moderate Buy” by Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has earned an average recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $32.20.

DNLI has been the topic of several recent analyst reports. UBS Group assumed coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. Wedbush lowered their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Morgan Stanley reissued an “overweight” rating and set a $40.00 price target on shares of Denali Therapeutics in a research report on Thursday, January 8th. Finally, Wolfe Research assumed coverage on Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. This represents a 5.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. The trade was a 10.60% decrease in their position. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DNLI. Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics in the second quarter worth $26,000. Johnson Financial Group Inc. acquired a new stake in Denali Therapeutics during the third quarter valued at $29,000. State of Wyoming purchased a new position in Denali Therapeutics in the second quarter valued at about $29,000. Aster Capital Management DIFC Ltd purchased a new position in Denali Therapeutics in the fourth quarter valued at about $57,000. Finally, Quarry LP acquired a new position in Denali Therapeutics in the 3rd quarter worth about $64,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $21.43 on Wednesday. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $23.77. The firm’s 50 day simple moving average is $19.59 and its 200-day simple moving average is $17.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The company has a market cap of $3.40 billion, a P/E ratio of -7.22 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same quarter in the previous year, the company posted ($0.67) earnings per share. As a group, equities research analysts predict that Denali Therapeutics will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.